HIV and Cocaine exposure promote Tau phosphorylation through RSK-1 in a GSK3β-independent manner.

This study identifies RSK1 as a central, GSK3β-independent mediator that drives Tau phosphorylation in response to both HIV and cocaine exposure, revealing a convergent signaling mechanism that contributes to neurocognitive dysfunction and suggesting RSK1 inhibition as a potential therapeutic strategy for Tau-associated pathologies.

The Gist

The Big Picture: A Traffic Jam in the Brain

Imagine your brain is a bustling city. The neurons (brain cells) are the buildings, and Tau proteins are the internal scaffolding or steel beams that hold those buildings upright and keep the elevators (cargo transport) moving smoothly.

For the city to function, these steel beams need to be the right size and shape. Sometimes, they get "tagged" with little sticky notes (phosphorylation). A few tags are normal, but if the beams get over-tagged, they start to clump together, lose their shape, and the building collapses. This is what happens in diseases like Alzheimer's and in the brain damage caused by HIV and cocaine.

This study asks: What is the "foreman" in the brain factory that is handing out all these extra sticky notes when people use cocaine or have HIV?

The Discovery: The "Master Foreman" (RSK1)

The researchers found that the answer isn't the usual suspect. For years, scientists thought a worker named GSK3β was the main one tagging the beams. But this study discovered a new, powerful foreman named RSK1.

Here is how the two troublemakers, HIV and Cocaine, hijack the brain, but in slightly different ways:

1. The HIV Strategy: The "Direct Order"

• The Scenario: HIV doesn't actually infect the brain cells directly (the cells don't have the front door key). Instead, the virus sends out toxic messengers (proteins) that knock on the door.
• The Action: These messengers scream at the brain cell to wake up. This wakes up the RSK1 foreman immediately and aggressively.
• The Result: RSK1 grabs a megaphone and starts handing out sticky notes to the Tau beams, causing them to clump up.
• The Twist: Interestingly, HIV turns off the old foreman (GSK3β). Usually, if you turn off the main tagger, the tagging should stop. But because RSK1 is so loud and powerful, it ignores the fact that GSK3β is off and keeps tagging the beams anyway.

2. The Cocaine Strategy: The "Double Team"

• The Scenario: Cocaine hits the brain cell and triggers a different set of alarms.
• The Action: Cocaine wakes up RSK1 (the new foreman), but it also wakes up a second foreman named AKT.
• The Result: AKT helps turn off the old foreman (GSK3β), just like HIV did. But because both RSK1 and AKT are working together, the tagging of the Tau beams goes into overdrive.
• The Twist: Even though the "brake" (GSK3β) is cut, the car (Tau pathology) keeps speeding because RSK1 is the real engine.

The "Aha!" Moment: The Brake Doesn't Work

The most surprising part of the study is this: Turning off the "brake" (GSK3β) doesn't stop the damage.

In the past, scientists thought that if you could just stop GSK3β, you would stop the brain damage. This study shows that's wrong. Even when GSK3β is completely disabled, RSK1 keeps the damage going. It's like trying to stop a runaway train by cutting the brakes on the back car, while the engine (RSK1) is still roaring at full speed.

The Proof: Knocking Out the Foreman

To prove RSK1 was the real culprit, the scientists did a "genetic surgery." They used a tool (CRISPR) to remove the RSK1 gene from the brain cells.

• What happened? The sticky notes stopped. The Tau beams stayed healthy.
• The Lesson: Without RSK1, neither HIV nor cocaine could cause the brain damage. RSK1 is the essential link.

Why This Matters: A New Way to Fix the City

This study changes how we think about treating brain damage in people with HIV or cocaine addiction.

• Old Idea: Try to fix the brakes (GSK3β).
• New Idea: We need to calm down the RSK1 foreman.

The researchers tested a "calming agent" (a drug inhibitor) that specifically told RSK1 to stop working. When they did this, the brain cells stopped getting damaged, even when exposed to HIV or cocaine.

The Bottom Line

Think of RSK1 as the Master Switch for brain damage in these conditions.

• HIV flips the switch on RSK1 directly.
• Cocaine flips the switch on RSK1 and helps it along with a sidekick (AKT).
• Both ignore the fact that the old safety system (GSK3β) is broken.

By identifying RSK1 as the main villain, this study opens the door to new medicines. Instead of trying to fix the broken brakes, doctors might one day be able to give patients a pill that tells the RSK1 foreman to "stand down," potentially saving the brain from the collapse caused by HIV and drug abuse.

In short: The study found the "boss" of the brain damage (RSK1) and showed that if you fire the boss, the damage stops, regardless of whether the patient has HIV or uses cocaine.

Technical Summary

1. Problem Statement

HIV-associated neurocognitive disorders (HAND) and substance abuse (specifically cocaine) are significant comorbidities that accelerate cognitive decline and neurodegeneration. While both factors are known to disrupt neuronal signaling and contribute to Tau pathology (hyperphosphorylation), the specific molecular mechanisms remain unclear.

• The Gap: Neurons are not productively infected by HIV (lacking CD4 receptors) but suffer indirect injury via viral proteins and inflammatory cytokines. Similarly, cocaine exacerbates neurodegeneration, but the convergence of HIV and cocaine signaling on Tau phosphorylation is poorly understood.
• The Paradox: Glycogen Synthase Kinase 3 beta (GSK3β) is traditionally considered a primary kinase for Tau phosphorylation. However, its activity is typically inhibited by AKT-mediated phosphorylation at Ser9. The authors observed that while HIV and cocaine exposure lead to GSK3β inactivation (via Ser9 phosphorylation), Tau phosphorylation paradoxically increases. This suggests the existence of a GSK3β-independent pathway driving Tau pathology.

2. Methodology

The study employed a multi-faceted approach using 2D cell cultures, 3D spheroids, and human brain organoids to ensure biological relevance.

• Cell Models:
  • H80 Cells: A novel glioma-derived neuronal cell line characterized in this study as expressing neuronal markers (NeuN, MAP2, Tau) and the HIV co-receptor CXCR4 (but lacking CD4/CCR5), making it suitable for studying HIV-induced neurotoxicity without productive infection.
  • Comparative Models: SH-SY5Y neuroblastoma cells, mixed 3D spheroids (H80 + SH-SY5Y + Microglia), and human iPSC-derived cerebral organoids (hCOs).
• Experimental Treatments:
  • HIV Exposure: H80 cells were exposed to HIV virions (strain 93/TH/051) via spinoculation.
  • Cocaine Exposure: Chronic (48h, twice daily) and acute (15 min to 6h) exposure to cocaine hydrochloride.
• Genetic and Pharmacological Manipulation:
  • CRISPR/Cas9: Generation of RSK1 (RPS6KA1) knockout (KO) H80 cells.
  • Overexpression: Transient transfection of RSK1 expression plasmids.
  • Inhibitors: Use of BI-D1870 (selective RSK1 inhibitor) and CHIR99021 (selective GSK3β inhibitor).
• Analytical Techniques:
  • Immunoblotting: To quantify phosphorylation states of RSK1, AKT, GSK3β, and Tau (specifically p-Tau S396).
  • Immunofluorescence: To visualize protein localization and expression.
  • qPCR: To assess inflammatory cytokine (IL-1β, TNF-α) and RSK1 mRNA levels.
  • Flow Cytometry: To profile HIV entry receptors (CD4, CCR5, CXCR4) on H80 cells.

3. Key Contributions

1. Characterization of H80 Cells: Validated H80 cells as a robust, neuronal-like model expressing NeuN, MAP2, and Tau, and possessing the CXCR4 co-receptor, making them ideal for studying indirect HIV neurotoxicity.
2. Identification of RSK1 as the Master Regulator: Established Ribosomal S6 Kinase 1 (RSK1) as the central signaling hub linking both HIV and cocaine exposure to Tau phosphorylation.
3. Discovery of a GSK3β-Independent Pathway: Demonstrated that Tau phosphorylation persists and is driven even when GSK3β is inactivated, overturning the assumption that active GSK3β is required for Tau pathology in these contexts.
4. Delineation of Divergent Upstream Mechanisms:
   • HIV: Drives Tau phosphorylation primarily through robust, AKT-independent upregulation and activation of RSK1.
   • Cocaine: Drives Tau phosphorylation through a dual mechanism: strong activation of AKT (leading to GSK3β inactivation) and moderate activation of RSK1.
5. Hierarchical Signaling Map: Defined RSK1 as an upstream regulator that positively controls AKT activation and negatively regulates (inactivates) GSK3β, creating a complex signaling network that converges on Tau.

4. Key Results

• Neuronal Phenotype of H80: H80 cells express NeuN and MAP2 (confirming neuronal lineage) and CXCR4, but lack CD4 and CCR5. They respond to HIV exposure by upregulating inflammatory cytokines (IL-1β, TNF-α) without productive viral replication.
• RSK1 Activation: Both HIV and cocaine exposure rapidly and robustly activate RSK1 (phosphorylation at Ser380, Thr348, Thr359/Ser363). HIV induces a stronger RSK1 response than cocaine.
• Tau Phosphorylation: Both stimuli significantly increase phosphorylation of Tau at Ser396 (a pathological marker). This occurs via post-translational modification, not increased Tau protein expression.
• The GSK3β Paradox Resolved:
  • Both HIV and cocaine induce phosphorylation of GSK3β at Ser9, effectively inactivating the kinase.
  • Despite GSK3β inactivation, Tau phosphorylation increases.
  • Inhibition Studies: Inhibiting GSK3β (CHIR99021) did not reduce Tau phosphorylation. Conversely, inhibiting RSK1 (BI-D1870) or knocking out RSK1 (CRISPR) abolished Tau phosphorylation, even when GSK3β was active.
• AKT Divergence:
  • Cocaine: Strongly activates AKT (p-AKT Thr308/Ser473), which contributes to GSK3β inactivation.
  • HIV: Does not activate AKT. It inactivates GSK3β solely through the RSK1 pathway.
• RSK1 as an Upstream Hub:
  • Knockout: RSK1 KO reduced AKT phosphorylation and total AKT levels, reactivated GSK3β, and eliminated p-Tau S396.
  • Overexpression: RSK1 overexpression increased p-AKT and p-GSK3β (Ser9), confirming RSK1 drives both AKT activation and GSK3β inhibition.
• Conservation Across Models: The RSK1-driven, GSK3β-independent mechanism was validated in SH-SY5Y cells, 3D spheroids, and human brain organoids, confirming biological robustness.

5. Significance

• Mechanistic Insight: The study redefines the signaling hierarchy in neurodegeneration, positioning RSK1 as a critical upstream node that integrates viral (HIV) and chemical (cocaine) stressors to drive Tauopathy.
• Therapeutic Target: RSK1 is identified as a "druggable" master regulator. Targeting RSK1 could mitigate Tau pathology in both HIV-associated neurocognitive disorders (HAND) and cocaine-induced neurodegeneration, potentially offering a unified treatment strategy for comorbid patients.
• Paradigm Shift: The findings challenge the dogma that GSK3β activity is strictly required for Tau hyperphosphorylation, revealing a dominant GSK3β-independent pathway mediated by RSK1.
• Model Utility: The validation of H80 cells as a reliable neuronal model provides a new tool for high-throughput screening of neurotoxicity and therapeutic interventions in neuro-HIV research.

In conclusion, the paper establishes that HIV and cocaine converge on RSK1 to drive pathological Tau phosphorylation. While they utilize distinct upstream routes (HIV: RSK1-only; Cocaine: RSK1 + AKT), the downstream outcome is a GSK3β-independent accumulation of phosphorylated Tau, driven by RSK1 acting as a central signaling hub.